Last reviewed · How we verify
BRII-835
BRII-835 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.
BRII-835 is a monoclonal antibody that targets the SARS-CoV-2 spike protein. Used for Treatment of COVID-19.
At a glance
| Generic name | BRII-835 |
|---|---|
| Sponsor | Brii Biosciences Limited |
| Drug class | Monoclonal antibody |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 2 |
Mechanism of action
BRII-835 works by binding to the SARS-CoV-2 spike protein, preventing the virus from entering host cells. This mechanism of action is similar to other monoclonal antibodies that have been developed to treat COVID-19.
Approved indications
- Treatment of COVID-19
Common side effects
- Injection site reaction
- Fatigue
- Headache
Key clinical trials
- Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) (PHASE2)
- Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) (PHASE2)
- Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRII-835 CI brief — competitive landscape report
- BRII-835 updates RSS · CI watch RSS
- Brii Biosciences Limited portfolio CI